Bayer plans label expansion for Kerendia after Phase 3 win in heart failure
Bayer touted a win in a Phase 3 heart failure study with Kerendia on Monday, announcing that the drug hit the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
